Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
21h
The company’s diversification across wealth management, asset management, and insurance muddies the company’s financials, and investors might discount the company’s valuation because of this.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback